| Name | Title | Contact Details |
|---|---|---|
Michael Bastian |
Chief Intellectual Property Counsel | Profile |
Agnieszka Gallagher |
Chief Legal Officer | Profile |
Nicholas Khadder |
SVP, General Counsel and Corporate Secretary | Profile |
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.
Founded in 2010, Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
Noramco, Inc. is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.